Asset Details
Do you wish to reserve the book?
Subtype-specific dysregulation of biogenic amine-related genes and miRNAs in breast cancer: identification of DRD2, HRH2, and HRH4 as potential therapeutic targets in TNBC and HER2+ subtypes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Subtype-specific dysregulation of biogenic amine-related genes and miRNAs in breast cancer: identification of DRD2, HRH2, and HRH4 as potential therapeutic targets in TNBC and HER2+ subtypes
Do you wish to request the book?
Subtype-specific dysregulation of biogenic amine-related genes and miRNAs in breast cancer: identification of DRD2, HRH2, and HRH4 as potential therapeutic targets in TNBC and HER2+ subtypes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Subtype-specific dysregulation of biogenic amine-related genes and miRNAs in breast cancer: identification of DRD2, HRH2, and HRH4 as potential therapeutic targets in TNBC and HER2+ subtypes
2025
Overview
Purpose
Biogenic amines (BAs) are known to influence tumorigenesis, yet their precise role in breast cancer remains unclear. This study aimed to investigate the expression patterns of BA-related genes, proteins, and their regulatory miRNAs across different breast cancer subtypes to identify potential biomarkers and therapeutic targets.
Methods
A cohort of 501 breast cancer patients was classified into luminal A (
n
= 130), luminal B HER2− (
n
= 100), luminal B HER2+ (
n
= 96), non-luminal HER2+ (
n
= 36), and triple-negative breast cancer (TNBC;
n
= 43). Gene expression was assessed via microarray analysis and validated using RT-qPCR. Protein levels were quantified using ELISA, while miRNA profiling was conducted to identify post-transcriptional regulatory interactions. Statistical significance was determined using ANOVA and Tukey’s post-hoc test (
p
< 0.05).
Results
Histamine-related genes (HRH1-HRH4) were upregulated across all subtypes, with HRH2 and HRH4 most elevated in TNBC (FC = 7.18,
p
< 0.01). DRD2 showed widespread upregulation (FC = 15.98,
p
< 0.001), whereas DRD5 was markedly downregulated, especially in non-luminal HER2+ tumors (FC = − 13.01,
p
< 0.01). miRNA analysis revealed downregulation of hsa-miR-30b-3p and hsa-miR-372-5p in TNBC and HER2+ subtypes, correlating with HRH2 and HRH4 overexpression (
p
< 0.05). EGR1 and ICAM1 exhibited strong subtype-specific expression, with ICAM1 significantly upregulated in TNBC (FC = 25.76,
p
< 0.001).
Conclusion
Subtype-specific dysregulation of BA-related genes and miRNAs suggests their involvement in tumor progression, immune modulation, and metabolic regulation. The findings highlight potential therapeutic targets, particularly in TNBC and HER2+ subtypes.
Publisher
Springer US,Springer Nature B.V
Subject
/ Aged
/ Amines
/ Biogenic Amines - metabolism
/ Biomarkers, Tumor - genetics
/ Female
/ Gene Expression Regulation, Neoplastic
/ Humans
/ Intercellular adhesion molecule 1
/ Medicine
/ miRNA
/ Oncology
/ Receptor, ErbB-2 - metabolism
/ Receptors, Dopamine D2 - genetics
/ Receptors, Dopamine D2 - metabolism
/ Receptors, G-Protein-Coupled - genetics
/ Receptors, G-Protein-Coupled - metabolism
/ Triple Negative Breast Neoplasms - drug therapy
/ Triple Negative Breast Neoplasms - genetics
/ Triple Negative Breast Neoplasms - metabolism
/ Triple Negative Breast Neoplasms - pathology
/ Tumors
